Evidence map›Paper›PMID 36862715›Full record

ArticlePloS one2023

Acss2/HIF-2 signaling facilitates colon cancer growth and metastasis.

Joseph A Garcia, Rui Chen, Min Xu, Sarah A Comerford, Robert E Hammer, Shelby D Melton, Linda A Feagins

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. The Effect of HIF-2International journal of inflammation · 2025
    Review
  7. Article
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Joseph A GarciaDepartment of Medicine, Columbia University Medical Center, New York, New York, United States of America.ORCID 0000-0002-5621-7538
Rui ChenDepartment of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America.
Min XuDepartment of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America.
Sarah A ComerfordDepartment of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America.
Robert E HammerDepartment of Biochemistry, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America.
Shelby D MeltonPathology & Laboratory Medicine, Veterans Affairs North Texas Health Care System, Dallas, Texas, United States of America.
Linda A FeaginsDepartment of Internal Medicine, Dell Medical School, The University of Texas at Austin, Austin, Texas, United States of America.
The University of Texas Southwestern Medical Center · USColumbia University Irving Medical Center · USThe University of Texas at Austin · USVA North Texas Health Care System · US

Funding

UT Southwestern Medical Center Simmons Comprehensive Cancer CenterP30CA142543 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Sandi Leigh Pruitt · 2010 to 2026
$53.7M
Mechanistic Studies and Translational Applications of Stress Signaling in AnemiaR01HL130142 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI GARCIA, JOSEPH ANTHONY · 2016 to 2019
$1.6M
Molecular mechanisms dictating Sirt1/HIF-2 signaling during hypoxiaR01HL108104 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI GARCIA, JOSEPH ANTHONY · 2011 to 2014
$1.3M
Dynamic Regulation of Erythropoietin Gene Expression in Mammals.I01BX000446 · VA · VA NORTH TEXAS HEALTH CARE SYSTEM · PI Joseph Anthony Garcia · 2009 to 2026
–
First-in-class small molecules for treatment of soft tissue sarcoma and other cancers associated with Agent Orange exposureI21BX006263 · VA · JAMES J PETERS VA MEDICAL CENTER · PI GARCIA, JOSEPH ANTHONY · 2024 to 2025
–
BLRD VA I01 BX000446BLRD VA I21 BX006263NCI NIH HHS P30 CA142543NHLBI NIH HHS R01 HL108104NHLBI NIH HHS R01 HL130142
6 · The paper itself

Abstract

The microenvironment of solid tumors is characterized by oxygen and glucose deprivation. Acss2/HIF-2 signaling coordinates essential genetic regulators including acetate-dependent acetyl CoA synthetase 2 (Acss2), Creb binding protein (Cbp), Sirtuin 1 (Sirt1), and Hypoxia Inducible Factor 2α (HIF-2α). We previously shown in mice that exogenous acetate augments growth and metastasis of flank tumors derived from fibrosarcoma-derived HT1080 cells in an Acss2/HIF-2 dependent manner. Colonic epithelial cells are exposed to the highest acetate levels in the body. We reasoned that colon cancer cells, like fibrosarcoma cells, may respond to acetate in a pro-growth manner. In this study, we examine the role of Acss2/HIF-2 signaling in colon cancer. We find that Acss2/HIF-2 signaling is activated by oxygen or glucose deprivation in two human colon cancer-derived cell lines, HCT116 and HT29, and is crucial for colony formation, migration, and invasion in cell culture studies. Flank tumors derived from HCT116 and HT29 cells exhibit augmented growth in mice when supplemented with exogenous acetate in an Acss2/HIF-2 dependent manner. Finally, Acss2 in human colon cancer samples is most frequently localized in the nucleus, consistent with it having a signaling role. Targeted inhibition of Acss2/HIF-2 signaling may have synergistic effects for some colon cancer patients.

Indexed as

Colonic NeoplasmsFibrosarcomaAcetate-CoA LigaseAnimalsBasic Helix-Loop-Helix ProteinsHumansMiceSignal TransductionTumor MicroenvironmentAcetate-CoA LigaseACSS2 protein, humanBasic Helix-Loop-Helix Proteins

Identifiers

PMID36862715
PMCPMC9980813
OpenAlexW4322758234

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.